19/11/2025
https://www.instagram.com/p/DRIJfnHgp0H/?utm_source=ig_web_copy_link&igsh=NTc4MTIwNjQ2YQ==
Injectable peptides have become the newest “regenerative solution” in aesthetic medicine, but they’re simply the latest stop on a long chain of regenerative claims.
We’ve progressed through PRP/PRF, stem cells, exosomes, polynucleotides and PDGF, each introduced with impressive terminology but weak to nonexistent clinical data.
That sequence normalises the idea that unlicensed aesthetic biologics and untested compounds could be injected for aesthetic benefit.
Injectable peptides such as BPC-157, TB-500, GHK-Cu, and other compounded blends are now being used and promoted in practice with:
- No approved aesthetic indication
- No long-term safety data
- No standardisation
- Significant variability in purity and sourcing
We are not seeing innovation – we are seeing escalation where patients are effectively the test subjects.
Once hype becomes the standard, the threshold for evidence quietly disappears.
Injectable peptides are the current apex, but they won’t be the last. PDGF opened the floodgates.
Credit: Dr Harris Clinic